UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A real world analysis of recurrence risk factors for early colorectal cancer T1 treated with standard endoscopic resection

International journal of colorectal disease, 2020-05, Vol.35 (5), p.921-927

2020

Volltextzugriff (PDF)

P-082Three years of metastatic gastric cancer follow up in our hospital

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii25-ii25

2016

Volltextzugriff (PDF)

P-051Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii15-ii16

2016

Volltextzugriff (PDF)

CP-144 Firstline triplet or doublet chemotherapy for HER2 negative advanced oesophagogastric cancer: an analysis from a community practice registry

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A65-A65

2017

Volltextzugriff (PDF)

1641P Patient preferences towards the application of telemedicine on cancer care during Coronavirus disease 2019 (COVID-19) pandemic. ONCOTELEMED STUDY

Annals of oncology, 2021-09, Vol.32, p.S1159-S1160

2021

Volltextzugriff (PDF)

1638P Experience with telemedicine during COVID-19 pandemic

Annals of oncology, 2021-09, Vol.32, p.S1158-S1159

2021

Volltextzugriff (PDF)

469P 16-year outcomes of radically treated localized gastric cancer (GC) patients (pt): Real-world data (RWD) of a Spanish institution

Annals of oncology, 2024-06, Vol.35, p.S188-S188

2024

Volltextzugriff (PDF)

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)

Annals of oncology, 2019-07, Vol.30, p.iv52-iv52

2019

Volltextzugriff (PDF)

76P Association of clinicopathological (C-P) features and tumor (tum) immune contexture with dissemination pattern in metastatic colorectal cancer (mCRC)

Annals of oncology, 2024-06, Vol.35, p.S37-S38

2024

Volltextzugriff (PDF)

595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)

Annals of oncology, 2023-10, Vol.34, p.S430-S431

2023

Volltextzugriff (PDF)

Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study)

Annals of oncology, 2018-06, Vol.29, p.v78-v78

2018

Volltextzugriff (PDF)

1410P Gastric cancer: Data from the AGAMENON-SEOM study

Annals of oncology, 2021-09, Vol.32, p.S1060-S1060

2021

Volltextzugriff (PDF)

P-082 Three years of metastatic gastric cancer follow up in our hospital

Annals of oncology, 2016-06, Vol.27, p.ii25-ii25

2016

Volltextzugriff (PDF)

P-191Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)

Annals of oncology, 2019-07, Vol.30 (Supplement_4)

2019

Volltextzugriff (PDF)

P-277Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study)

Annals of oncology, 2018-06, Vol.29 (suppl_5)

2018

Volltextzugriff (PDF)

4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A96-A97

2023

Volltextzugriff (PDF)

P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)

Annals of oncology, 2016-06, Vol.27, p.ii15-ii15

2016

Volltextzugriff (PDF)

116P RETROSPECTIVE ANALYSIS OF PATIENTS WITH THYMIC MALIGNANCIES TREATED AT THE VALL D'HEBRON UNIVERSITY HOSPITAL

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S50-S50

2013

Volltextzugriff (PDF)

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017-05, Vol.20 (3), p.465-474

2017

Volltextzugriff (PDF)

Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study

Cancers, 2023-09, Vol.15 (18), p.4603

2023

Volltextzugriff (PDF)

Evaluation of comprehensive geriatric assessment impact in oncological decision-making process

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e24020-e24020

2021

Volltextzugriff (PDF)

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231157641-17588359231157641

2023

Volltextzugriff (PDF)

Treatment in esophagogastric junction cancer: Past, present and future

Cirugia española (English ed.), 2019-10, Vol.97 (8), p.459-464

2019

Volltextzugriff (PDF)

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211019672

2021

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A real world analysis of recurrence risk factors for early colorectal cancer T1 treated with standard endoscopic resection

P-082Three years of metastatic gastric cancer follow up in our hospital

P-051Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)

CP-144 Firstline triplet or doublet chemotherapy for HER2 negative advanced oesophagogastric cancer: an analysis from a community practice registry

1641P Patient preferences towards the application of telemedicine on cancer care during Coronavirus disease 2019 (COVID-19) pandemic. ONCOTELEMED STUDY

1638P Experience with telemedicine during COVID-19 pandemic

469P 16-year outcomes of radically treated localized gastric cancer (GC) patients (pt): Real-world data (RWD) of a Spanish institution

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)

76P Association of clinicopathological (C-P) features and tumor (tum) immune contexture with dissemination pattern in metastatic colorectal cancer (mCRC)

595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)

560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial

Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study)

1410P Gastric cancer: Data from the AGAMENON-SEOM study

P-082 Three years of metastatic gastric cancer follow up in our hospital

P-191Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)

P-277Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study)

4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment

P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)

116P RETROSPECTIVE ANALYSIS OF PATIENTS WITH THYMIC MALIGNANCIES TREATED AT THE VALL D'HEBRON UNIVERSITY HOSPITAL

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study

Evaluation of comprehensive geriatric assessment impact in oncological decision-making process

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Treatment in esophagogastric junction cancer: Past, present and future

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Suchergebnisse filtern